Randall Dere

1.6k total citations
20 papers, 748 citations indexed

About

Randall Dere is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pathology and Forensic Medicine. According to data from OpenAlex, Randall Dere has authored 20 papers receiving a total of 748 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 13 papers in Radiology, Nuclear Medicine and Imaging and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Randall Dere's work include Monoclonal and Polyclonal Antibodies Research (13 papers), HER2/EGFR in Cancer Research (12 papers) and Lymphoma Diagnosis and Treatment (9 papers). Randall Dere is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (13 papers), HER2/EGFR in Cancer Research (12 papers) and Lymphoma Diagnosis and Treatment (9 papers). Randall Dere collaborates with scholars based in United States, France and Switzerland. Randall Dere's co-authors include Surinder Kaur, Ola M. Saad, Montserrat Carrasco‐Triguero, Keyang Xu, Dan Lü, Yanhong Li, Priya Agarwal, Joo‐Hee Yi, Elaine Mai and David E. Allison and has published in prestigious journals such as Journal of Clinical Oncology, Advanced Drug Delivery Reviews and Clinical Cancer Research.

In The Last Decade

Randall Dere

18 papers receiving 686 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Randall Dere United States 12 529 461 221 164 134 20 748
Ainura Kyshtoobayeva United States 13 420 0.8× 169 0.4× 441 2.0× 43 0.3× 59 0.4× 18 859
Gustavo Ismael Belgium 6 296 0.6× 150 0.3× 128 0.6× 64 0.4× 32 0.2× 10 495
Arthur Kunz United States 13 555 1.0× 515 1.1× 237 1.1× 120 0.7× 160 1.2× 17 865
Yanxia Shi China 18 571 1.1× 141 0.3× 311 1.4× 89 0.5× 55 0.4× 76 982
Howard Grossberg United States 8 432 0.8× 180 0.4× 270 1.2× 106 0.6× 26 0.2× 12 743
J Ritschard Switzerland 8 278 0.5× 769 1.7× 299 1.4× 139 0.8× 89 0.7× 12 918
D Marx Germany 13 255 0.5× 80 0.2× 254 1.1× 59 0.4× 65 0.5× 20 451
J. Mills United Kingdom 11 290 0.5× 185 0.4× 253 1.1× 40 0.2× 39 0.3× 21 671
Guorong Yang China 8 611 1.2× 269 0.6× 369 1.7× 37 0.2× 33 0.2× 19 920
Bradley M. Turner United States 14 440 0.8× 231 0.5× 146 0.7× 19 0.1× 103 0.8× 45 759

Countries citing papers authored by Randall Dere

Since Specialization
Citations

This map shows the geographic impact of Randall Dere's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Randall Dere with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Randall Dere more than expected).

Fields of papers citing papers by Randall Dere

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Randall Dere. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Randall Dere. The network helps show where Randall Dere may publish in the future.

Co-authorship network of co-authors of Randall Dere

This figure shows the co-authorship network connecting the top 25 collaborators of Randall Dere. A scholar is included among the top collaborators of Randall Dere based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Randall Dere. Randall Dere is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schofield, CJ, Randall Dere, Juliane Siebourg‐Polster, et al.. (2025). Proteomics approach identifies aqueous humor biomarkers in retinal diseases. Communications Medicine. 5(1). 134–134. 4 indexed citations
2.
Eichenbaum, David, Arshad M. Khanani, Dante J. Pieramici, et al.. (2025). Phase 2 Study of the Anti-High Temperature Requirement A1 (HtrA1) Fab Galegenimab (FHTR2163) in Geographic Atrophy Secondary to Age-Related Macular Degeneration. American Journal of Ophthalmology. 275. 14–26.
3.
Liao, Michael Z., Dan Lu, Tong Lu, et al.. (2024). Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings. Advanced Drug Delivery Reviews. 207. 115193–115193. 2 indexed citations
4.
5.
Deng, Rong, Leonid Gibiansky, Tong Lu, et al.. (2024). Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study. CPT Pharmacometrics & Systems Pharmacology. 13(6). 1055–1066. 4 indexed citations
6.
Liao, Michael Z., Rong Deng, Leonid Gibiansky, et al.. (2023). Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non‐Asian patients with previously untreated diffuse large B‐cell lymphoma in POLARIX. Clinical and Translational Science. 16(12). 2744–2755. 3 indexed citations
7.
Dere, Randall, Richard L. Beardsley, Dan Lü, et al.. (2023). Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. Frontiers in Immunology. 14. 1119510–1119510. 4 indexed citations
8.
Shemesh, Colby S., Priya Agarwal, Tong Lu, et al.. (2020). Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. Cancer Chemotherapy and Pharmacology. 85(5). 831–842. 11 indexed citations
9.
10.
Li, Dongwei, Randall Dere, Bing Zheng, et al.. (2019). Evaluation and use of an anti‐cynomolgus monkey CD79b surrogate antibody–drug conjugate to enable clinical development of polatuzumab vedotin. British Journal of Pharmacology. 176(19). 3805–3818. 23 indexed citations
11.
Carrasco‐Triguero, Montserrat, et al.. (2019). Immunogenicity of Antibody–drug Conjugates: Observations Across 8 Molecules in 11 Clinical Trials. Bioanalysis. 11(17). 1555–1568. 39 indexed citations
12.
Lü, Dan, Tong Lu, Leonid Gibiansky, et al.. (2019). Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma. CPT Pharmacometrics & Systems Pharmacology. 9(1). 48–59. 30 indexed citations
13.
Advani, Ranjana H., Daniel Lebovic, Andy Chen, et al.. (2016). Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Clinical Cancer Research. 23(5). 1167–1176. 65 indexed citations
14.
Fuh, Franklin, Dongwei Li, Kirsten Achilles Poon, et al.. (2016). Anti‐CD22 and anti‐CD79b antibody‐drug conjugates preferentially target proliferating B cells. British Journal of Pharmacology. 174(8). 628–640. 20 indexed citations
15.
Lü, Dan, Jin Y. Jin, Sandhya Girish, et al.. (2014). Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys. Pharmaceutical Research. 32(6). 1907–1919. 19 indexed citations
16.
Dere, Randall, Joo‐Hee Yi, Ola M. Saad, et al.. (2013). PK Assays for Antibody–Drug Conjugates: Case Study with Ado-Trastuzumab Emtansine. Bioanalysis. 5(9). 1025–1040. 50 indexed citations
17.
Carrasco‐Triguero, Montserrat, Joo‐Hee Yi, Randall Dere, et al.. (2013). Immunogenicity Assays for Antibody–Drug Conjugates: Case Study with Ado-Trastuzumab Emtansine. Bioanalysis. 5(9). 1007–1023. 38 indexed citations
18.
Xu, Keyang, Luna Liu, Randall Dere, et al.. (2013). Characterization of The Drug-To-Antibody Ratio Distribution for Antibody–Drug Conjugates in Plasma/Serum. Bioanalysis. 5(9). 1057–1071. 79 indexed citations
19.
Kaur, Surinder, Keyang Xu, Ola M. Saad, Randall Dere, & Montserrat Carrasco‐Triguero. (2013). Bioanalytical Assay Strategies for The Development of Antibody–Drug Conjugate Biotherapeutics. Bioanalysis. 5(2). 201–226. 157 indexed citations
20.
Gordon, Michael S., Daniela Matei, Carol Aghajanian, et al.. (2006). Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status. Journal of Clinical Oncology. 24(26). 4324–4332. 187 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ainura Kyshtoobayeva Breakdown of academic impact, for papers by Gustavo Ismael Breakdown of academic impact, for papers by Arthur Kunz Breakdown of academic impact, for papers by Yanxia Shi Breakdown of academic impact, for papers by Howard Grossberg Breakdown of academic impact, for papers by J Ritschard Breakdown of academic impact, for papers by D Marx Breakdown of academic impact, for papers by J. Mills Breakdown of academic impact, for papers by Guorong Yang Breakdown of academic impact, for papers by Bradley M. Turner
Rankless by CCL
2026